A Double-blinded, Randomized, Placebo-Controlled Phase I

Project: Research project

Project Details

Description

A Double-blinded, Randomized, Placebo-Controlled Phase III Study to assess the efficacy of reMAGE-A3 + AS15 ASCI as Adjuvant therapy in Patients with MAGE-A3 Positive Resected Stage III Melanoma
StatusFinished
Effective start/end date7/31/087/31/13

Funding

  • GlaxoSmithKline

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.